Navigation Links
NeurogesX to Present at Piper Jaffray Health Care Conference
Date:11/24/2009

dge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza(TM) (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. NeurogesX expects to launch Qutenza in United States in the first half of 2010 for patients with postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc.

The Company's second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.

The Company's early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the safety and efficacy of Qutenza(TM); the timing of launch of Qutenza; and development activities for NGX-1998 and other product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: any regulatory approvals which are received may be limited to certain indications; Qutenza and NeurogesX' other product candidates may have unexpected adverse side eff
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. NeurogesX Reports Third Quarter 2009 Results
2. NeurogesX to Present at Two November Conferences
3. NeurogesX to Present at UBS Global Life Sciences Conference
4. NeurogesX to Present at Upcoming Fall Conferences
5. NeurogesX Appoints New Board Director and Audit Committee Chairman
6. NeurogesX Reports Second Quarter 2009 Results
7. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
8. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
9. NeurogesX Added to Russell 3000 Index
10. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
11. NeurogesX to Present at Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2013)... Lake, MN (PRWEB) June 20, 2013 Over ... trade show displays, has received many questions that can be ... display for me?” Owner of GLM Displays, Matt Lunser, ... describe the differences between his products and offer some useful ... shows and expos. , “This buyer's guide is meant to ...
(Date:6/20/2013)... Belatrix Software, the leading global Nearshore ... its latest initiative – the Belatrix Software Innovation University ... leaders, and business and technology executives to participate in ... of the initiative is to fuel business leaders with ... product innovation efforts. It’s that inspiration that has ...
(Date:6/20/2013)... Sturgeon Bay, WI (PRWEB) June 20, 2013 ... rich in Omega-3 fatty acids, according to Sturgeon ... G Moellendorf, DC, ND, LCP . Recent research ... in increased health and decreased disease. , Researcher Janice ... College of Medicine in Columbus have studied the health ...
(Date:6/20/2013)... Dental decay is the number one chronic disease ... Crisafulli of Crisafulli Dental those statistics are no longer daunting. ... and implemented a cavity prevention program developed by CariFree that ... to 74% . The system is known as ... a solution to dental decay that works,” says Dr. Crisafulli, ...
Breaking Biology Technology:Belatrix Software Kicks off Major Innovation Effort and Invites Innovation Expert to Share How Agile + Design Thinking Accelerate Product Innovation 2Omega-3 Fatty Acids: the Fountain of Youth? 2Omega-3 Fatty Acids: the Fountain of Youth? 3Omega-3 Fatty Acids: the Fountain of Youth? 4Crisafulli Dental Launches Ground Breaking Cavity Prevention Program That Can Lower Decay Rates by 74% 2
... Sigma-Aldrich Corporation,(Nasdaq: SIAL ) will be presenting at ... 25th at 1:00 PM ET in New York. ... the,Internet available at http://ir.sigmaaldrich.com . Users can click ... on, http://ir.sigmaaldrich.com users will need to have Media ...
... ROCKVILLE, Md., Sept. 14 Human Genome,Sciences, Inc. (Nasdaq: ... the,Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference in ... http://www.hgsi.com (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) ... will present,an overview of the company on Tuesday, September ...
... Sept. 14 Palatin,Technologies, Inc. (Amex: PTN ) announced ... 30, 2007. Palatin reported a net loss of,$6.1 million, or ... 30, 2007, compared to a net loss of $7.9 million, ... in 2006. Total revenues in the,quarter ended June 30, 2007 ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 2Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 3Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 4Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 5Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 6Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 7Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 8
(Date:6/19/2013)... team of researchers at the University of Pittsburgh ... coating of HIV, that could be potential treatments ... generating resistance. These new agents are quite small, ... research was published in the June 2013 issue ... . , The first of many probable applications ...
(Date:6/19/2013)... MedNet Solutions , a global life ... is pleased to announce its participation in the 2013 ... Boston .  This represents the 10 ... cloud-based eClinical solutions, has exhibited at this premier industry ... iMedNet™ EDC , MedNet,s latest, easy-to-use eClinical technology ...
(Date:6/19/2013)... potent physiological anabolic agent for tissue-building and energy ... protein and carbohydrates, and inhibiting their breakdown and ... a major role in stimulating glucose entry into ... removed from the blood following meals. But gaps ... which insulin regulates glucose uptake in fat and ...
Breaking Biology News(10 mins):HIV-derived antibacterial shows promise against drug-resistant bacteria 2MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2
... target muscle may reverse the symptoms of a rare ... mice conducted by medical geneticists at Duke University Medical ... Pompe disease usually die before they reach the age ... targeting corrective genes to muscles may have application in ...
... the flow of water molecules through the brain can help ... if a patient's tumor will shrink, a new study shows. ... developed the assessment, which they call a functional diffusion map. ... diffusion, or movement, of water through the brain and mapped ...
... historic anthropology expedition to Ethiopia's Lake Turkana basin, researchers ... time are roughly 195,000 years old. The researchers ... we all trace to an ancient line that first ... recently as 50,000 years ago. , Ian McDougall of ...
Cached Biology News:Muscle-targeted gene therapy reverses rare muscular dystrophy in mice 2Muscle-targeted gene therapy reverses rare muscular dystrophy in mice 3New imaging method gives early indication if brain cancer therapy is effective, U-M study shows 2New imaging method gives early indication if brain cancer therapy is effective, U-M study shows 3New Clues Add 40,000 Years to Age of Human Species 2New Clues Add 40,000 Years to Age of Human Species 3New Clues Add 40,000 Years to Age of Human Species 4
... particle based purification systems provide high speed ... sample. They offer increased throughput and reproducible ... KingFisher, KingFisher mL and KingFisher 96, covering ... Each system consists of an instrument, specially ...
... PROTECT FROM MOISTURE. AVOID FREEZE/THAW CYCLES. ... cells in vitro by DNA ... their anti-histone-facilitated detection. In this assay, mono- ... binding proteins. Anti-Histone 3 (H3) biotin-labeled antibody ...
... optimized cell lines in combination with ... nucleofection parameters. Nucleofector Kits are only ... Device., Different cell lines can be ... efficiencies and viabilities are given in ...
... solution or in a gel piece, we can ... be digested to produce a mixture of peptides. ... determined by MALDI-TOF, and the amino acid sequences ... will be determined by MALDI-TOF/TOF. The masses and ...
Biology Products: